Immunologic markers of cancer progression and prognosis

Pankaj Singhal, Nana E. Tchabo, Kunle Odunsi

Research output: Contribution to journalArticle

Abstract

During the past decade, significant progress has been made in understanding the interactions between the immune system and cancer. The re-emergence of cancer immunosurveillance and immunoediting concepts has provided an understanding of several immunologic markers that are associated with cancer progression and prognosis. Recent studies have attempted to define the critical role of tumor infiltration by lymphocytes as a reflection of a tumor-related immune response. More recently, there has been an improved ability to demonstrate distinct subsets of tumor-infiltrating lymphocytes (TILs) in different tumor compartments. Several of these studies indicate that the presence of TILs may be associated with improved clinical outcome in several human cancers. However, this improved clinical outcome is dependent upon the intratumoral balance and quality of TILs, or infiltration of regulatory T cells or myeloid-derived suppressor cells. Immunologic markers have an important role in demonstrating intermediate end points of a therapeutic intervention and ultimately may be useful in predicting clinical outcomes. These markers are important to the development of successful immunotherapy strategies in cancer.

Original languageEnglish (US)
Pages (from-to)439-450
Number of pages12
JournalExpert Opinion on Medical Diagnostics
Volume1
Issue number4
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Tumors
Lymphocytes
Biomarkers
Tumor-Infiltrating Lymphocytes
Neoplasms
Infiltration
T-cells
Immune system
Immunologic Monitoring
Regulatory T-Lymphocytes
Immunotherapy
Immune System

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Molecular Medicine
  • Biochemistry, medical

Cite this

Singhal, Pankaj ; Tchabo, Nana E. ; Odunsi, Kunle. / Immunologic markers of cancer progression and prognosis. In: Expert Opinion on Medical Diagnostics. 2007 ; Vol. 1, No. 4. pp. 439-450.
@article{98b353fda29e427d9ae18eab44abb7c0,
title = "Immunologic markers of cancer progression and prognosis",
abstract = "During the past decade, significant progress has been made in understanding the interactions between the immune system and cancer. The re-emergence of cancer immunosurveillance and immunoediting concepts has provided an understanding of several immunologic markers that are associated with cancer progression and prognosis. Recent studies have attempted to define the critical role of tumor infiltration by lymphocytes as a reflection of a tumor-related immune response. More recently, there has been an improved ability to demonstrate distinct subsets of tumor-infiltrating lymphocytes (TILs) in different tumor compartments. Several of these studies indicate that the presence of TILs may be associated with improved clinical outcome in several human cancers. However, this improved clinical outcome is dependent upon the intratumoral balance and quality of TILs, or infiltration of regulatory T cells or myeloid-derived suppressor cells. Immunologic markers have an important role in demonstrating intermediate end points of a therapeutic intervention and ultimately may be useful in predicting clinical outcomes. These markers are important to the development of successful immunotherapy strategies in cancer.",
author = "Pankaj Singhal and Tchabo, {Nana E.} and Kunle Odunsi",
year = "2007",
month = "12",
day = "1",
doi = "10.1517/17530059.1.4.439",
language = "English (US)",
volume = "1",
pages = "439--450",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "4",

}

Immunologic markers of cancer progression and prognosis. / Singhal, Pankaj; Tchabo, Nana E.; Odunsi, Kunle.

In: Expert Opinion on Medical Diagnostics, Vol. 1, No. 4, 01.12.2007, p. 439-450.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunologic markers of cancer progression and prognosis

AU - Singhal, Pankaj

AU - Tchabo, Nana E.

AU - Odunsi, Kunle

PY - 2007/12/1

Y1 - 2007/12/1

N2 - During the past decade, significant progress has been made in understanding the interactions between the immune system and cancer. The re-emergence of cancer immunosurveillance and immunoediting concepts has provided an understanding of several immunologic markers that are associated with cancer progression and prognosis. Recent studies have attempted to define the critical role of tumor infiltration by lymphocytes as a reflection of a tumor-related immune response. More recently, there has been an improved ability to demonstrate distinct subsets of tumor-infiltrating lymphocytes (TILs) in different tumor compartments. Several of these studies indicate that the presence of TILs may be associated with improved clinical outcome in several human cancers. However, this improved clinical outcome is dependent upon the intratumoral balance and quality of TILs, or infiltration of regulatory T cells or myeloid-derived suppressor cells. Immunologic markers have an important role in demonstrating intermediate end points of a therapeutic intervention and ultimately may be useful in predicting clinical outcomes. These markers are important to the development of successful immunotherapy strategies in cancer.

AB - During the past decade, significant progress has been made in understanding the interactions between the immune system and cancer. The re-emergence of cancer immunosurveillance and immunoediting concepts has provided an understanding of several immunologic markers that are associated with cancer progression and prognosis. Recent studies have attempted to define the critical role of tumor infiltration by lymphocytes as a reflection of a tumor-related immune response. More recently, there has been an improved ability to demonstrate distinct subsets of tumor-infiltrating lymphocytes (TILs) in different tumor compartments. Several of these studies indicate that the presence of TILs may be associated with improved clinical outcome in several human cancers. However, this improved clinical outcome is dependent upon the intratumoral balance and quality of TILs, or infiltration of regulatory T cells or myeloid-derived suppressor cells. Immunologic markers have an important role in demonstrating intermediate end points of a therapeutic intervention and ultimately may be useful in predicting clinical outcomes. These markers are important to the development of successful immunotherapy strategies in cancer.

UR - http://www.scopus.com/inward/record.url?scp=80052134586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052134586&partnerID=8YFLogxK

U2 - 10.1517/17530059.1.4.439

DO - 10.1517/17530059.1.4.439

M3 - Article

C2 - 23496352

AN - SCOPUS:80052134586

VL - 1

SP - 439

EP - 450

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 4

ER -